SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community grapples with mixed sentiments amidst ongoing price stagnation, despite some believing a potential merger involving Zero Hash and Mastercard, alongside progress on the Clarity Act, could be catalysts. Many holders are expressing frustration over consistent declines, while others are actively accumulating, pointing to Flexa's real-world utility with major merchants and recent patents as reasons for long-term optimism. The debate rages between those who see it as a foundational payment collateral token and those who fear it's a 'dead project' that continually disappoints.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing highly polarized sentiment, with many in the community expressing frustration over significant losses and year-end tax-loss selling contributing to downward pressure. Despite widespread discussions questioning its utility and sustained underperformance relative to other major cryptocurrencies, a dedicated segment of holders maintains long-term conviction, eagerly anticipating a future resurgence.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending with a massive volume surge and price rally following news of a strategic manufacturing partnership aimed at scaling production of its drug screening reader for future U.S. market entry. The community is intensely divided, with bulls pointing to the low float and the positive impact of a $10 million private placement on its balance sheet, while bears express significant concern over dilution, the company's reverse split history, and the offering's terms.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to massive trading volume and a significant price surge, sparking intense community discussion around its low-float SPAC nature. Traders are actively anticipating further upward movement and a potential squeeze, drawing parallels to other recently explosive micro-cap plays that have experienced rapid ascents.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is generating significant buzz as a low-float SPAC, with traders actively discussing its potential for a substantial price run. The community is drawing strong parallels to recent 'shell company rippers' like ESHA, anticipating a considerable upward movement fueled by limited circulating shares and growing speculative interest.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its new integration with a Stripe-owned fiat anchor, which enables seamless, compliant bank-to-stablecoin transfers at a verified 11 million transactions per second. The community sees it as a potentially undervalued Layer 1 blockchain, poised to become essential financial infrastructure for institutions by offering high-speed, regulated settlement rails. This focus on enterprise-grade plumbing for global finance differentiates it from many other crypto projects.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant upward momentum as the FDA granted Priority Review for its AXS-05 in Alzheimer's disease agitation, with a PDUFA target date of April 30, and confirmed a clear path for its AXS-12 narcolepsy treatment. This major regulatory progress, alongside robust Auvelity sales growth and numerous analyst price target increases, has ignited strong bullish sentiment across the community. Many are celebrating long-term holdings and are optimistic about Axsome's potential to capitalize on substantial market opportunities in CNS disorders.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with significant community anticipation for the start of a new yearly cycle, driving strong bullish sentiment for substantial long-term gains. Many investors are actively accumulating, citing historical patterns that suggest an imminent upward trajectory. The discussion is marked by strong convictions from bulls, despite ongoing skepticism from bears regarding its immediate outlook.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending amid intense community debate, primarily driven by widespread shareholder frustration with CEO Richard Paulson and the board, whom many accuse of continuous value destruction and mismanagement. Recent financing and a reverse stock split, while extending the cash runway, have amplified concerns about dilution and executive accountability. Despite this pervasive negative sentiment toward leadership, significant bullish options activity and anticipation for upcoming Phase 3 trial readouts in Myelofibrosis and Endometrial Cancer highlight an underlying belief in the company's scientific potential, contingent on a change in management.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is trending due to recent strategic moves, including pipeline expansion through acquisitions and manufacturing advancements for its lead anticoagulant candidate, Tecarfarin. The market is weighing the potential of these developments, including analyst-assigned price targets and FDA designations, against community concerns about cash burn, dilution, and the company's ability to fund pivotal Phase 3 trials. This creates a polarized discussion, highlighting the high-stakes nature of micro-cap biopharma investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Cool Company Ltd. (CLCO) Stock Outpacing Its Transportation Peers This Year?

Here is how Cool Company Ltd. (CLCO) and Cathay Pacific Airways Ltd. (CPCAY) have performed compared to their sector so far this year.

Should Value Investors Buy Cathay Pacific Airways (CPCAY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Transportation Stocks Lagging  Cathay Pacific Airways (CPCAY) This Year?

Here is how Cathay Pacific Airways Ltd. (CPCAY) and Okeanis Eco Tankers Corp. (ECO) have performed compared to their sector so far this year.

Are Investors Undervaluing Cathay Pacific Airways (CPCAY) Right Now?

Is Global Ship Lease (GSL) Outperforming Other Transportation Stocks This Year?

Here is how Global Ship Lease (GSL) and Cathay Pacific Airways Ltd. (CPCAY) have performed compared to their sector so far this year.

Is Cathay Pacific Airways (CPCAY) Stock Undervalued Right Now?

Is Cathay Pacific Airways (CPCAY) Outperforming Other Transportation Stocks This Year?

Here is how Cathay Pacific Airways Ltd. (CPCAY) and LATAM (LTM) have performed compared to their sector so far this year.

Cathay Pacific said on Wednesday that it would buy 14 Boeing widebody jets for about $8 billion to boost its fleet after posting a rise in profit in the first half of the year.The Hong Kong-based airline said it expects to receive the 777-9 airplanes by 2034 and has received significant discounts from the planemaker. It will also have the option to purchase seven more Boeing wide-body jets.Cathay said that the order came as the company exercised its option to purchase the aircraft under a 2013 agreement. The airline now has 35 777X orders on its books, making it one of the largest operators of the wide-body aircraft in the world.“Designed to reduce fuel use and emissions on average by 20% and noise by 40% compared to the airplanes it replaces, the 777-9 will enable Cathay Pacific to efficiently meet growing air travel demand across key global markets,” Boeing said in a statement.Retail sentiment on Stocktwits about <a href="https://stocktwits.com/symbol/BA">Boeing</a> was in the ‘bearish’ territory at the time of writing.<figure class="image"><img style="aspect-ratio:728/85;" src="https://news.stocktwits-cdn.com/BA_Aug_6_JPG_2f36f1c40c.webp" alt=" BA’s Sentiment Meter and Message Volume as of 02:47 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="728" height="85"><figcaption> BA’s Sentiment Meter and Message Volume as of 02:47 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>The 777-9 is the latest version in the 777 series and is yet to be certified by the U.S. Federal Aviation Administration. Boeing CEO Kelly Ortberg had said last month that the company is doing flight tests and expects to begin deliveries next year.The Cathay deal is another major win for Boeing this year, as this was the first 777x order placed by the airline in over a decade. Boeing’s backlog has surged past $500 billion as airlines scramble to bolster their fleet amid an expected surge in passenger traffic.Boeing stock has gained 26% this year.Separately, Cathay reported a 1.1% rise in net profit to 3.65 billion Hong Kong dollars ($465 million) for the first six months of 2025, compared to the same period a year earlier. The company attributed the uptick to higher passenger volume and lower fuel prices, which offset lower yields resulting from expanded capacity."Despite the uncertainties caused by tariffs and changes to the de minimis exemption, our cargo business demonstrated resilience," CEO Patrick Healy noted about cargo traffic.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kremlin-says-us-russia-relations-will-take-time-to-improve-after-hitting-unprecedented-lows-under-biden/chr1NN0RdPJ">Kremlin Says US-Russia Relations ‘Will Take Time’ To Improve After Hitting ‘Unprecedented’ Lows Under Biden</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Cathay Pacific aircraft at Sydney's Kingsford Smith International airport on August 25, 2021 in Sydney, Australia.

Boeing Scores Big Win With $8B Cathay Pacific Order For 14 Widebody Jets

The Hong Kong-based airline said it expects to receive the 777-9 airplanes by 2034 and has received significant discounts from the planemaker.

Equity

Cathay Pacific: UBS flags modest impact from U.S. visa curbs on Chinese students

Investing.com -- UBS analysts believe that potential U.S. government actions to revoke visas for Chinese students and tighten application reviews will have a "manageable demand impact" on Cathay Pacific’s revenue. 

Cathay Pacific posts marginal profit growth in 2024 as ticket prices normalize

Investing.com-- Cathay Pacific Airways (HK:0293) reported a marginal rise in annual profit on Wednesday, as gains from robust travel demand were partially offset by higher costs and normalizing ticket prices.

Cathay Pacific Airways Ltd. engages in the operation of scheduled airline services, airline catering, aircraft handling, cargo terminal operations and loyalty, and reward programmes. It operates through the following segments: Cathay Pacific, HK Express, Air Hong Kong, and Airline Services. The HK Express segment offers passenger carrier scheduled services. The Air Hong Kong segment provides express cargo air transportation offering scheduled services. The Airline Services segment includes catering, cargo terminal operations, ground handling services, and commercial laundry operations. The Associates segment handles companies which hold a substantial long-term interest in equity share capital. The company was founded by Roy C. Farrell and Sydney H. de Kantzow on September 24, 1946 and is headquartered in Hong Kong.

CPCAY
Cathay Pacific

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPCAY News

CPCAYCathay Pacific